Targeting the lysosome: Mechanisms and treatments for nonalcoholic fatty liver disease

Pu, Jing

doi:10.1002/jcb.30274

Cited by 9 publications

(5 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that lysosomes are closely related to the processes of lipid metabolism. [52][53][54] Therefore, we examined the quantity and function of lysosomes in hepatocytes to investigate whether the ameliorative effect of Ace Pg3G on lipid deposition was related to lysosomes. Also, given that Pg3G did not display a positive effect on oxidative stress or lipid deposition, subsequent experiments to explore the mechanism will focus on Ace Pg3G.…”

Section: Ace Pg3g Increased Lysosomal Quantity and Enhanced Lysosomal...mentioning

confidence: 99%

Acetylated pelargonidin-3-O-glucoside alleviates hepatocyte lipid deposition through activating the AMPK-mediated lysosome-autophagy pathway and redox state

Xie,

Hao,

Xie

et al. 2024

Food Funct.

View full text Add to dashboard Cite

show abstract

Section: Ace Pg3g Increased Lysosomal Quantity and Enhanced Lysosomal...mentioning

confidence: 99%

Acetylated pelargonidin-3-O-glucoside alleviates hepatocyte lipid deposition through activating the AMPK-mediated lysosome-autophagy pathway and redox state

Xie,

Hao,

Xie

et al. 2024

Food Funct.

View full text Add to dashboard Cite

show abstract

“… 72 Therefore, reactivation of ALP via regulation of the mTORC1–TFEB axis has great therapeutic potential in MAFLD treatment. 124 …”

Section: The Effects and Functional Targets Of Natural Products In Th...mentioning

confidence: 99%

The cellular and molecular targets of natural products against metabolic disorders: a translational approach to reach the bedside

Shen,

Yang,

Yang

et al. 2024

MedComm

View full text Add to dashboard Cite

Metabolic disorders, including obesity, dyslipidemia, diabetes, nonalcoholic fatty liver disease, and metabolic syndrome, are characterized by insulin resistance, abnormalities in circulating cholesterol and lipid profiles, and hypertension. The most common pathophysiologies of metabolic disorders are glucose/lipid metabolism dysregulation, insulin resistance, inflammatory response, and oxidative stress. Although several agents have been approved for the treatment of metabolic disorders, there is still a strong demand for more efficacious drugs with less side effects. Natural products have been critical sources of drug research and discovery for decades. However, the usefulness of bioactive natural products is often limited by incomplete understanding of their direct cellular targets. In this review, we highlight the current understanding of the established and emerging molecular mechanisms of metabolic disorders. We further summarize the therapeutic effects and underlying mechanisms of natural products on metabolic disorders, with highlights on their direct cellular targets, which are mainly implicated in the regulation of glucose/lipid metabolism, insulin resistance, metabolic inflammation, and oxidative stress. Finally, this review also covers the clinical studies of natural products in metabolic disorders. These progresses are expected to facilitate the application of these natural products and their derivatives in the development of novel drugs against metabolic disorders.

show abstract

“…Interestingly, the strategy of targeting the lysosome has seemed to encourage a new direction for future NAFLD treatment, e.g. , inhibition of mTOR localized on the lysosome surface and restoration of normal lysosomal function and autophagy[ 75 ]. Nevertheless, all of the studies are limited to animal models.…”

Section: Challenges In Treatmentmentioning

confidence: 99%

Challenges in pediatric inherited/metabolic liver disease: Focus on the disease spectrum, diagnosis and management of relatively common disorders

Zou¹,

Wang²,

Li³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

The clinical scenario of pediatric liver disease is becoming more intricate due to changes in the disease spectrum, in which an increasing number of inherited/ metabolic liver diseases are reported, while infectious diseases show a decreasing trend. The similar clinical manifestations caused by inherited/metabolic diseases might be under-recognized or misdiagnosed due to nonspecific characteristics. A delayed visit to a doctor due to a lack of symptoms or mild symptoms at an early stage will result in late diagnosis and treatment. Moreover, limited diagnostic approaches, especially liver biopsy, are not easily accepted by pediatric patients, leading to challenges in etiological diagnosis. Liver dysfunction due to inherited/metabolic diseases is often caused by a variety of metabolites, so precision treatment is difficult; symptomatic treatment is a compelling option for inherited disorders.

show abstract

Targeting the lysosome: Mechanisms and treatments for nonalcoholic fatty liver disease

Cited by 9 publications

References 107 publications

Acetylated pelargonidin-3-O-glucoside alleviates hepatocyte lipid deposition through activating the AMPK-mediated lysosome-autophagy pathway and redox state

Acetylated pelargonidin-3-O-glucoside alleviates hepatocyte lipid deposition through activating the AMPK-mediated lysosome-autophagy pathway and redox state

The cellular and molecular targets of natural products against metabolic disorders: a translational approach to reach the bedside

Challenges in pediatric inherited/metabolic liver disease: Focus on the disease spectrum, diagnosis and management of relatively common disorders

Contact Info

Product

Resources

About